<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-IIR-16007806</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2016-01-20</date_registration>
      <primary_sponsor>Department of Hematology, Xinqiao Hospital, Third Military Medical University</primary_sponsor>
      <public_title>Clincal study of umbilical cord-derived mesenchymal stem cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem cell transpantation--multicenter, randomized parallel controlled, double-blind trial</public_title>
      <acronym />
      <scientific_title>Clincal study of umbilical cord-derived mesenchymal stem cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem cell transpantation</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2016-04-01</date_enrolment>
      <type_enrolment />
      <target_size>MSCs group:78;normal saline group:78;</target_size>
      <recruitment_status>Pending</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=13052</url>
      <study_type>Interventional study</study_type>
      <study_design>Randomized parallel controlled trial</study_design>
      <phase>II (Phase II study)</phase>
      <hc_freetext>HLA-haploidentical hematopoietic stem cell transplantation patients with hematologic malignancies</hc_freetext>
      <i_freetext>MSCs group:infusion umbilical cord-derived MSCs 1*10^6/kg per 15 days, total 4 times;normal saline group:infusion same volume normal saline;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Lei Gao</firstname>
        <middlename />
        <lastname />
        <address>183 Xinqiao Main Street, Chongqing, China</address>
        <city />
        <country1 />
        <zip>400037</zip>
        <telephone>+86 13228689635</telephone>
        <email>gaolei7765@163.com</email>
        <affiliation>Department of Hematology, Xinqiao Hospital, Third Military Medical University</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Xi Zhang</firstname>
        <middlename />
        <lastname />
        <address>183 Xinqiao Main Street, Chongqing, China</address>
        <city />
        <country1 />
        <zip>400037</zip>
        <telephone>+86 13808310064</telephone>
        <email>zhangxxi@sina.com</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. HLA-haploidentical HSCT patients did not occured GVHD; 
2. Age between 18 to 60;
3. KPS score &gt; 60;
4. No serious organ dysfunction;
5. Expected survival &gt; 3 months.</inclusion_criteria>
      <agemin>18</agemin>
      <agemax>60</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. Have serious organ dysfunction;
2. Combined with other cancer need treatment;
3. Presence of clinical signs of brain dysfuntion or severe mental illness can not comply with the study protocol;
4. Can not scheduled follow-up;
5. Can not guarantee the completion of the treatment plan and the necessary follow-up observation.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Chronic graft versus host disease;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Relapse;Overall survival;Disease free survival;Security;Lymphocyte subset;</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>XDA01000000</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2015-12-31</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>